HRP20201137T1 - Intranazalni pripravak koji sadrži betahistin - Google Patents

Intranazalni pripravak koji sadrži betahistin Download PDF

Info

Publication number
HRP20201137T1
HRP20201137T1 HRP20201137TT HRP20201137T HRP20201137T1 HR P20201137 T1 HRP20201137 T1 HR P20201137T1 HR P20201137T T HRP20201137T T HR P20201137TT HR P20201137 T HRP20201137 T HR P20201137T HR P20201137 T1 HRP20201137 T1 HR P20201137T1
Authority
HR
Croatia
Prior art keywords
betahistine
dose
pharmaceutical preparation
day
preparation
Prior art date
Application number
HRP20201137TT
Other languages
English (en)
Croatian (hr)
Inventor
Christopher John Wraight
Thomas Meyer
Original Assignee
Otolanum Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otolanum Ag filed Critical Otolanum Ag
Publication of HRP20201137T1 publication Critical patent/HRP20201137T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20201137TT 2017-02-02 2018-02-02 Intranazalni pripravak koji sadrži betahistin HRP20201137T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762453931P 2017-02-02 2017-02-02
PCT/EP2018/052695 WO2018141922A1 (en) 2017-02-02 2018-02-02 Intranasal composition comprising betahistine
EP18703749.4A EP3474850B1 (en) 2017-02-02 2018-02-02 Intranasal composition comprising betahistine

Publications (1)

Publication Number Publication Date
HRP20201137T1 true HRP20201137T1 (hr) 2021-01-22

Family

ID=61187302

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20201137TT HRP20201137T1 (hr) 2017-02-02 2018-02-02 Intranazalni pripravak koji sadrži betahistin
HRP20231706TT HRP20231706T1 (hr) 2017-02-02 2018-02-02 Intranazalni pripravak koji sadrži betahistin

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20231706TT HRP20231706T1 (hr) 2017-02-02 2018-02-02 Intranazalni pripravak koji sadrži betahistin

Country Status (33)

Country Link
US (2) US10456386B2 (enExample)
EP (2) EP3474850B1 (enExample)
JP (3) JP7714323B2 (enExample)
KR (1) KR102653545B1 (enExample)
CN (2) CN118356397A (enExample)
AR (1) AR111699A1 (enExample)
AU (1) AU2018216970B2 (enExample)
CA (1) CA3051725A1 (enExample)
CL (1) CL2019002145A1 (enExample)
CO (1) CO2019008657A2 (enExample)
DK (2) DK3698791T3 (enExample)
EA (1) EA201991817A1 (enExample)
ES (2) ES2969301T3 (enExample)
FI (1) FI3698791T3 (enExample)
HR (2) HRP20201137T1 (enExample)
HU (2) HUE065336T2 (enExample)
IL (1) IL268353B2 (enExample)
LT (2) LT3698791T (enExample)
MA (1) MA46778B1 (enExample)
MX (1) MX381932B (enExample)
MY (1) MY196333A (enExample)
NZ (1) NZ755931A (enExample)
PH (1) PH12019501785B1 (enExample)
PL (2) PL3474850T3 (enExample)
PT (2) PT3474850T (enExample)
RS (2) RS60554B1 (enExample)
SA (1) SA519402324B1 (enExample)
SG (1) SG11201906980YA (enExample)
SI (2) SI3474850T1 (enExample)
TN (1) TN2019000220A1 (enExample)
TW (1) TWI760429B (enExample)
WO (1) WO2018141922A1 (enExample)
ZA (1) ZA201904955B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170532A1 (en) * 2017-03-22 2018-09-27 Franz, Lilian Ann Treatment method
EP4135658A1 (en) * 2020-04-14 2023-02-22 GlaxoSmithKline Consumer Healthcare Holdings (US) LLC Nasal spray formulation with moisturizing benefits
CN116209454A (zh) * 2020-04-22 2023-06-02 萨诺蒂泽研究开发公司 治疗上呼吸道感染的组合物和方法
WO2026062705A1 (en) 2024-09-23 2026-03-26 Troikaa Pharmaceuticals Limited Oromucosal liquid compositions of betahistine or its pharmaceutically acceptable salt(s) and processes for preparation thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397840B1 (enExample) 1977-07-22 1981-03-20 Cherqui Jean
IT1229237B (it) * 1989-05-08 1991-07-26 Prodotti Formenti Sali di (2-(piridil)etil) metilammina
JPH03287535A (ja) * 1990-03-31 1991-12-18 Bairon Boeki Kk プラノプロフェン水溶液
JP3203056B2 (ja) * 1992-08-13 2001-08-27 株式会社ティ・ティ・エス技術研究所 メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
JPH10139667A (ja) * 1996-11-15 1998-05-26 Yoshitomi Pharmaceut Ind Ltd 水性液剤
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
JP3555598B2 (ja) 2001-06-27 2004-08-18 株式会社村田製作所 積層型インダクタ
JP2004196676A (ja) * 2002-12-16 2004-07-15 Rohto Pharmaceut Co Ltd 点鼻剤
JP4733333B2 (ja) * 2002-12-26 2011-07-27 ライオン株式会社 点鼻剤又は洗鼻剤
ES2258694T3 (es) 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
CA2553309A1 (en) * 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
AU2006202950A1 (en) * 2004-04-22 2006-10-19 Mor Research Applications Ltd. Methods and Compositions for Weight Management
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
WO2007022345A2 (en) * 2005-08-17 2007-02-22 Fleming And Company, Pharmaceuticals Vitamin b12 nasal spray and method of use
WO2007076140A2 (en) 2005-12-23 2007-07-05 University Of Cincinnati Treatment methods employing histamine h3 receptor antagonists, including betahistine
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
BRPI0821647A2 (pt) * 2007-12-21 2015-06-16 Schering Plough Healthcare Realce da fotosestabillização de oximetazolina
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
ES2419204T3 (es) * 2008-05-27 2013-08-19 The University Of Melbourne Métodos para tratar a mamíferos con disfunciones de la trompa de Eustaquio
ES2589915T3 (es) * 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
WO2016049700A1 (en) * 2014-10-03 2016-04-07 Lachesis Biosciences Pty Ltd Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Also Published As

Publication number Publication date
SI3474850T1 (sl) 2020-09-30
EP3474850A1 (en) 2019-05-01
DK3474850T3 (da) 2020-08-03
PH12019501785A1 (en) 2020-07-06
JP2022051872A (ja) 2022-04-01
KR20190116341A (ko) 2019-10-14
CN118356397A (zh) 2024-07-19
PL3474850T3 (pl) 2020-09-21
CN110418643A (zh) 2019-11-05
US20180214432A1 (en) 2018-08-02
WO2018141922A1 (en) 2018-08-09
US10456386B2 (en) 2019-10-29
PH12019501785B1 (en) 2024-02-28
MX381932B (es) 2025-03-13
EP3698791B1 (en) 2023-10-25
RS65099B1 (sr) 2024-02-29
SG11201906980YA (en) 2019-08-27
JP2024019731A (ja) 2024-02-09
DK3698791T3 (da) 2024-01-15
MX2019008961A (es) 2019-10-15
TN2019000220A1 (en) 2021-01-07
MY196333A (en) 2023-03-24
HUE050829T2 (hu) 2021-01-28
AU2018216970B2 (en) 2023-12-21
EP3474850B1 (en) 2020-04-22
US20200022963A1 (en) 2020-01-23
PL3698791T3 (pl) 2024-04-08
TW201831179A (zh) 2018-09-01
ZA201904955B (en) 2021-05-26
JP2020506930A (ja) 2020-03-05
AU2018216970A1 (en) 2019-08-22
ES2969301T3 (es) 2024-05-17
NZ755931A (en) 2022-07-29
LT3698791T (lt) 2024-02-12
SA519402324B1 (ar) 2023-03-16
MA46778A1 (fr) 2021-04-30
FI3698791T3 (fi) 2024-01-11
SI3698791T1 (sl) 2024-05-31
PT3698791T (pt) 2024-01-12
CA3051725A1 (en) 2018-08-09
CO2019008657A2 (es) 2020-01-17
EP3698791A1 (en) 2020-08-26
PT3474850T (pt) 2020-07-27
CL2019002145A1 (es) 2019-11-04
KR102653545B1 (ko) 2024-04-04
HUE065336T2 (hu) 2024-05-28
MA46778B1 (fr) 2022-08-31
RS60554B1 (sr) 2020-08-31
AR111699A1 (es) 2019-08-14
BR112019015687A2 (pt) 2020-04-28
IL268353B2 (en) 2023-10-01
IL268353A (en) 2019-09-26
HRP20231706T1 (hr) 2024-03-15
EA201991817A1 (ru) 2020-01-27
ES2807798T3 (es) 2021-02-24
JP7714323B2 (ja) 2025-07-29
LT3474850T (lt) 2020-08-10
TWI760429B (zh) 2022-04-11
IL268353B1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
EP1755561B1 (en) Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines
FI3668509T3 (fi) Menetelmä hoitaa amyotrofista lateraaliskleroosia pridopidiinilla
KR20150011807A (ko) 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
HRP20120798T1 (hr) Kappa-opijatni agonisti za lijeäśenje dijareja-predominantnog i naizmjeniäśnog sindroma iritabilnog crijeva
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
KR20110045004A (ko) 충혈제거제 및 코르티코스테로이드를 포함하는 비강내 조성물
CA2522292A1 (en) Nasal pharmaceutical formulations and methods of using the same
JP2013511534A5 (enExample)
KR20040049849A (ko) 감기 치료용 조성물
JP2011520981A5 (enExample)
KR20120107970A (ko) 상승적 항바이러스 조성물 및 이의 용도
KR20110014199A (ko) 비강 비염 치료용 재조합 인간 cc10 및 이의 조성물
JP2020506930A5 (enExample)
WO2006017505A3 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
HRP20231706T1 (hr) Intranazalni pripravak koji sadrži betahistin
US12233066B2 (en) Combinations of inhibitors of influenza virus replication
JP2005512946A5 (enExample)
JP2016505050A5 (enExample)
CN101396364B (zh) 扎来普隆口腔给药系统或组合物及其制备方法
JP2009539893A (ja) 組合せウェーハ
KR20190009294A (ko) 비강 울혈을 치료/예방하기 위한 카르복실산
ES2357520T3 (es) Administración nasal de agentes para el tratamiento de emesis de inicio retardado.
JP5828007B2 (ja) 局所投与型の嚥下障害改善用医薬品
CN110833540B (zh) 一种柳酚咖敏片及其制备方法